128 related articles for article (PubMed ID: 37659203)
1. A state-of-art of underlying molecular mechanisms and pharmacological interventions/nanotherapeutics for cisplatin resistance in gastric cancer.
Gupta J; Ahmed AT; Tayyib NA; Zabibah RS; Shomurodov Q; Kadheim MN; Alsaikhan F; Ramaiah P; Chinnasamy L; Samarghandian S
Biomed Pharmacother; 2023 Oct; 166():115337. PubMed ID: 37659203
[TBL] [Abstract][Full Text] [Related]
2. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.
Wu Q; Ma J; Wei J; Meng W; Wang Y; Shi M
Mol Oncol; 2021 Jan; 15(1):299-316. PubMed ID: 32460412
[TBL] [Abstract][Full Text] [Related]
3. miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Gu Y; Fei Z; Zhu R
Anticancer Drugs; 2020 Apr; 31(4):385-393. PubMed ID: 31913198
[TBL] [Abstract][Full Text] [Related]
4. Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: Approaching to a new era of cancer chemotherapy.
Mirzaei S; Gholami MH; Hashemi F; Zabolian A; Hushmandi K; Rahmanian V; Entezari M; Girish YR; Sharath Kumar KS; Aref AR; Makvandi P; Ashrafizadeh M; Zarrabi A; Khan H
Life Sci; 2021 Jul; 277():119430. PubMed ID: 33789144
[TBL] [Abstract][Full Text] [Related]
5. Ubenimex induces autophagy inhibition and EMT suppression to overcome cisplatin resistance in GC cells by perturbing the CD13/EMP3/PI3K/AKT/NF-κB axis.
Guo Q; Jing FJ; Xu W; Li X; Li X; Sun JL; Xing XM; Zhou CK; Jing FB
Aging (Albany NY); 2019 Dec; 12(1):80-105. PubMed ID: 31895687
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance.
Wu QN; Liao YF; Lu YX; Wang Y; Lu JH; Zeng ZL; Huang QT; Sheng H; Yun JP; Xie D; Ju HQ; Xu RH
Cancer Lett; 2018 Jan; 412():243-255. PubMed ID: 29050982
[TBL] [Abstract][Full Text] [Related]
7. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells.
Zheng P; Chen L; Yuan X; Luo Q; Liu Y; Xie G; Ma Y; Shen L
J Exp Clin Cancer Res; 2017 Apr; 36(1):53. PubMed ID: 28407783
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
Cheng C; Qin Y; Zhi Q; Wang J; Qin C
Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
[TBL] [Abstract][Full Text] [Related]
9. Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling.
Fu D; Wang C; Yu L; Yu R
Cell Mol Biol Lett; 2021 Jun; 26(1):26. PubMed ID: 34098867
[TBL] [Abstract][Full Text] [Related]
10. Exosome-transmitted miR-769-5p confers cisplatin resistance and progression in gastric cancer by targeting CASP9 and promoting the ubiquitination degradation of p53.
Jing X; Xie M; Ding K; Xu T; Fang Y; Ma P; Shu Y
Clin Transl Med; 2022 May; 12(5):e780. PubMed ID: 35522909
[TBL] [Abstract][Full Text] [Related]
11. Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies.
Mirzaei S; Hushmandi K; Zabolian A; Saleki H; Torabi SMR; Ranjbar A; SeyedSaleh S; Sharifzadeh SO; Khan H; Ashrafizadeh M; Zarrabi A; Ahn KS
Molecules; 2021 Apr; 26(8):. PubMed ID: 33921908
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells.
Zheng H; Wang JJ; Yang XR; Yu YL
World J Gastroenterol; 2020 Feb; 26(5):499-513. PubMed ID: 32089626
[TBL] [Abstract][Full Text] [Related]
13. Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance.
Mirzaei S; Mohammadi AT; Gholami MH; Hashemi F; Zarrabi A; Zabolian A; Hushmandi K; Makvandi P; Samec M; Liskova A; Kubatka P; Nabavi N; Aref AR; Ashrafizadeh M; Khan H; Najafi M
Pharmacol Res; 2021 May; 167():105575. PubMed ID: 33771701
[TBL] [Abstract][Full Text] [Related]
14. PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2.
Li H; Ma X; Yang D; Suo Z; Dai R; Liu C
J Cell Biochem; 2020 Feb; 121(2):1353-1361. PubMed ID: 31478258
[TBL] [Abstract][Full Text] [Related]
15. The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cells.
Wang Z; Wang Q; Xu G; Meng N; Huang X; Jiang Z; Chen C; Zhang Y; Chen J; Li A; Li N; Zou X; Zhou J; Ding Q; Wang S
RNA Biol; 2020 Nov; 17(11):1576-1589. PubMed ID: 31885317
[TBL] [Abstract][Full Text] [Related]
16. Exosome-Delivered c-Met siRNA Could Reverse Chemoresistance to Cisplatin in Gastric Cancer.
Zhang Q; Zhang H; Ning T; Liu D; Deng T; Liu R; Bai M; Zhu K; Li J; Fan Q; Ying G; Ba Y
Int J Nanomedicine; 2020; 15():2323-2335. PubMed ID: 32308384
[TBL] [Abstract][Full Text] [Related]
17. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway.
Zeng L; Liao Q; Zou Z; Wen Y; Wang J; Liu C; He Q; Weng N; Zeng J; Tang H; Fang R; Lei Z; Tang Z; Yang X; Cui S
Cell Physiol Biochem; 2018; 51(3):1221-1236. PubMed ID: 30481766
[TBL] [Abstract][Full Text] [Related]
18. PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128/ZEB1 axis.
Guo Y; Yue P; Wang Y; Chen G; Li Y
Biomed Pharmacother; 2019 Oct; 118():109255. PubMed ID: 31352238
[TBL] [Abstract][Full Text] [Related]
19. CAF-derived midkine promotes EMT and cisplatin resistance by upregulating lncRNA ST7-AS1 in gastric cancer.
Yang KD; Wang Y; Zhang F; Li QL; Luo BH; Feng DY; Zeng ZJ
Mol Cell Biochem; 2022 Nov; 477(11):2493-2505. PubMed ID: 35588343
[TBL] [Abstract][Full Text] [Related]
20. USP14 as a novel prognostic marker promotes cisplatin resistance via Akt/ERK signaling pathways in gastric cancer.
Fu Y; Ma G; Liu G; Li B; Li H; Hao X; Liu L
Cancer Med; 2018 Nov; 7(11):5577-5588. PubMed ID: 30296012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
